MELOXICAM Bioveta 1.5 mg/ml oral suspension for dogs
The form of administration is particularly suitable to relieve the chronic orthopedic pain, inflammation and fever in cases of need of repeated administration.
|type of preparative:||Other products|
|target species animals:||Dog|
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Each ml contains:
Meloxicam 1.5 mg
Sodium benzoate 5 mg
Yellow or green-yellow suspension.
Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders in dogs.
Do not use in pregnant and lactating animals.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in dogs under 6 weeks of age.
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. In very rare cases, haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been observed.
These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment. In very rare cases they may be serious or fatal.
If adverse reactions occur, discontinue treatment and consult a veterinarian.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION
Oral administration, in feed or directly into the animal’s mouth.
Shake well before use.
Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight, i.e. 1 ml of the product/7.5 kg bw on the first day. Treatment should be continued by administration of a maintenance dose of 0.1 mg meloxicam/kg body weight, i.e. 1 ml of the product/15 kg bw once daily at 24-hour intervals.
For longer term treatment, once a clinical response has been observed (after ≥ 4 days), the dose of the product can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculoskeletal disorders may vary over time.
Particular attention should be paid to accurate dosing.
A clinical response is normally seen within 3-4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.
Alternatively, therapy may be initiated with the veterinary medicinal product MELOXICAM Bioveta 5 mg/ml solution for injection.
Avoid introduction of contamination during use.
ADVICE ON CORRECT ADMINISTRATION
Shake well before use.
Not intended for food-producing animals.
SPECIAL STORAGE PRECAUTIONS
Keep out of the sight and reach of children.
Protect from frost.
Keep the vial in the carton in order to protect from light.
Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.
Shelf life after first opening the immediate packaging: 6 months.
Special precautions for use in animals:
Avoid use in dehydrated, hypovolaemic or hypotensive animals as there may be a potential risk of increased renal toxicity.
This product is intended for dogs and must not be given to cats because it is not suitable for this species.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to NSAID should avoid contact with the veterinary medicinal product.
In case of accidental ingestion seek medical advice immediately and show the package leaflet or label to the practitioner.
Pregnancy and lactation:
The safety of the veterinary medicinal product has not been established for use during pregnancy and lactation (see section 5).
Interaction with other medicinal products and other forms of interaction:
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. The product must not be administered in conjunction with other NSAIDs or glucocorticoids.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
Overdose (symptoms, emergency procedures, antidotes):
Symptomatic treatment should be initiated in case of overdose.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Medicines should not be disposed of via wastewater or household waste.
Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.
For animal treatment only.
Veterinary medicinal product subject to prescription.
10 ml, 30 ml, 100 ml
Not all pack sizes may be marketed.
+420 517 318 598